Boston Scientific beats Q1 revenue expectations, except for endoscopy sales

US-based Boston Scientific has publicized its first quarter report, which surpassed analysts’ revenue expectations.
Photo: Marcio Jose Sanchez/AP/Ritzau Scanpix
Photo: Marcio Jose Sanchez/AP/Ritzau Scanpix
by marketwire, translated by daniel pedersen

US-based medtech firm Boston Scientific, a competitor of Danish firm Ambu on the endoscopy market, has delivered Q1 results on both top and bottom lines that exceed estimations, though according to these, endoscopy sales have underperformed slightly.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading